Target intelligence / Profile preview

CD3 antigen (cluster of differentiation 3) (CD3)

Target
CD3
Molecular classification
Receptor-associated membrane protein complex, Immunoglobulin superfamily (the extracellular domains), Signal transduction accessory/protein
01

Overview

The CD3 antigen is a multimeric cell-surface complex found exclusively on T cells, composed of four invariant polypeptide chains—gamma (γ), delta (δ), epsilon (ε), and zeta (ζ)—that associate as three dimers (γε, δε, ζζ)[7][2]. CD3 is non-covalently bound to the T-cell receptor (TCR) and is critical for intracellular signaling upon antigen recognition. Its cytoplasmic tails contain immunoreceptor tyrosine-based activation motifs (ITAMs) that serve as docking and activation sites for kinases following TCR engagement, allowing T cell activation, proliferation, and cytokine release[2][1][7]. CD3 is a therapeutic target in immunology, with monoclonal antibodies and bispecific agents (such as blinatumomab) leveraging CD3 to redirect or suppress T cell activity in cancer, autoimmune diseases, and transplantation medicine[7][5]. CD3 expression is also used as a pan-T cell marker in laboratory diagnostics[7].\nThe original query refers to cytotoxicity mediated by CD3-positive cells—these are typically CD8+ cytotoxic T lymphocytes, but the molecular target is **CD3**, not the functional phenotype.

Other names
cluster of differentiation 3CD3 complexT-cell co-receptor
02

Mechanism of action

Antibody or biologic binding to CD3 triggers T cell activation and cytotoxicity, sometimes redirecting T cells against tumor or target cells\nCan induce depletion or modulation of T cells (immunosuppression)

03

Biological functions

T cell activationSignal transductionT cell maturation and developmentImmune response
04

Disease associations

CancerAutoimmune diseasesInfectionInflammationGraft-versus-host disease (GVHD)
05

Safety considerations

Cytokine release syndrome (CRS)Immunosuppression/infection risk (T cell depletion)Risk of autoimmunity or off-target cytotoxicity
06

Interacting drugs

Muromonab-CD3 (OKT3, anti-CD3 monoclonal antibody)

3 more in the full profile.

07

Biomarkers

CD3 expression (flow cytometry, immunohistochemistry as pan-T cell marker)T cell counts (immunomonitoring)

Beyond the preview

Go deeper on CD3 antigen (cluster of differentiation 3) (CD3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD3 antigen (cluster of differentiation 3) (CD3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call